EQS-News: M1 Kliniken AG: Strong Earnings Growth in 2024 – Strategic Focus on Global Market Leadership
|
EQS-News: M1 Kliniken AG
/ Key word(s): Annual Report/Dividend
M1 Kliniken AG: Strong Earnings Growth in 2024 – Strategic Focus on Global Market Leadership Berlin, 21/05/2025 - M1 Kliniken AG (ISIN: DE000A0STSQ8) today published its annual report for the 2024 financial year. The M1 Group continued on its growth trajectory, driven in particular by the high-margin Beauty segment. Looking ahead, the company sees substantial growth potential: revenues in the Beauty segment are expected to reach between EUR 200 and 300 million by 2029, with a targeted EBIT margin of at least 20%. The strategic goal is to establish M1 Med Beauty as the leading global brand for aesthetic treatments. M1 is already the market leader in Europe – offering the highest medical standards at the best price. With the proposed dividend of EUR 0.50 per share, the Management Board and Supervisory Board reaffirm the Group’s dividend policy. Key Financial Highlights 2024
Significant Increase in Profitability and Cash Flow The consolidated net profit after minority interests rose markedly to EUR 16.0 million in 2024 (previous year: EUR 10.3 million). Earnings per share increased accordingly from EUR 0.54 to EUR 0.85. Operating cash flow more than tripled to EUR 30.5 million (previous year: EUR 7.8 million), while free cash flow improved significantly to EUR 24.9 million, compared to EUR -1.5 million in the previous year. The full Annual Report 2024 is available for download at www.m1-kliniken.de. About M1 Kliniken AG M1 Kliniken AG is the leading fully integrated provider of aesthetic medical healthcare services in Europe and Australia. The Group offers products and services of the highest quality standards in the aesthetic and surgical fields. M1 currently offers beauty treatments at 58 clinics under the "M1 Med Beauty" brand. The M1 Schlossklinik for Plastic and Aesthetic Surgery in Berlin is one of the largest and most modern facilities of its kind in Europe, with six operating theaters and 35 beds. M1 has been driving forward its internationalization since the end of 2018 and is currently represented in ten countries. Contact: M1 Kliniken AG Grünauer Straße 5 12557 Berlin T: +49 (0)30 347 47 44 14 M: ir@m1-kliniken.de
21.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2141988 |
| End of News | EQS News Service |
|
|
2141988 21.05.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 77,27 | 159,59 | 314,61 | 285,29 | 316,32 | 339,18 | 349,00 | |
| EBITDA1,2 | 11,33 | 8,89 | 17,82 | 15,41 | 21,01 | 31,96 | 33,70 | |
| EBITDA-Margin3 | 14,66 | 5,57 | 5,66 | 5,40 | 6,64 | 9,42 | 9,66 | |
| EBIT1,4 | 7,93 | 4,41 | 12,13 | 9,35 | 15,70 | 26,75 | 28,20 | |
| EBIT-Margin5 | 10,26 | 2,76 | 3,86 | 3,28 | 4,96 | 7,89 | 8,08 | |
| Net Profit (Loss)1 | 9,73 | 7,43 | 10,88 | 7,07 | 11,67 | 17,79 | 18,80 | |
| Net-Margin6 | 12,59 | 4,66 | 3,46 | 2,48 | 3,69 | 5,25 | 5,39 | |
| Cashflow1,7 | -5,37 | 9,54 | 15,68 | 20,77 | 7,81 | 30,55 | 24,50 | |
| Earnings per share8 | 0,56 | 0,37 | 0,45 | 0,22 | 0,54 | 0,85 | 0,93 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,50 | 0,50 | 0,50 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: wetreu NTRG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| M1 Kliniken | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A0STSQ | DE000A0STSQ8 | AG | 379,51 Mio € | 14.09.2015 | Kaufen | 9F4MCHV9+6R |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 15,58 | 27,45 | 0,57 | 44,93 | 3,94 | 12,42 | 1,12 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,50 | 0,50 | 0,50 | 2,59% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 16.07.2025 | 05.06.2025 | 09.09.2025 | 18.11.2025 | 21.05.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +28,84% | +31,86% | +16,39% | +20,37% | +311,06% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
